Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
Recruiting now · Not applicable
Conditions studied: Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers, Risk of Hepatic Cancers, Risk of Lung Cancer, Risk of Skin Cancers Except Basal-cell Carcinomas, Risk of Head and Neck Cancers, Risk of Mesothelioma, Risk of Kidney Cancer, Risk of Prostate Cancer, Risk of Urothelial Cancers, Risk of Endocrine Cancers, Risk of Hematologic Malignancies, Risk of Several Cancer Types, Risk of Second Malignancy in Individuals Treated for a Childhood Cancer, Risk of Neoplasia
In brief
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.
Key facts
- Study ID
- NCT06907095
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
- People needed
- 5909
- Starts
- 2026-03-16
- Expected to finish
- 2030-06-01
- Last updated by the study team
- 2026-03-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Known prior diagnosis of cancer or hematological malignancy within the past 5 years except for non-melanoma skin cancers, in situ cervical cancers and for patients with germline TP53 alterations,
- Presence of signs or symptoms of cancer at enrolment,
- Acute exacerbation of an autoimmune condition requiring escalation in medical therapy within 14 days prior to enrolment,
- Any medical condition with a high likelihood of mortality within three years,
- Physical or psychological conditions considered not to be compatible with the study and not likely to comply with follow up requirements,
- Individuals under guardianship or deprived of their liberty by a judicial or administrative decision or incapable of giving their consent,
- Women carriers of (P) or (LP) variants in BRCA1, BRCA2, PALB2, gene considering prophylactic mastectomy in a near future or aged less than 40 years (since their absolute risk of cancer is lower than the expected threshold)
- Received a blood transfusion within the last week before inclusion.
Where it is running
- Gustave Roussy — Villejuif, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.